- Vertex Pharmaceuticals Inc on Wednesday said its triple-combination treatment for cystic fibrosis led to significant lung function improvement in two late-stage studies, paving the way for a therapy that could eventually address 90 percent of people with the life-shortening genetic condition.
The company had previously tested another experimental drug, VX-659, with the two-drug combination approved under the brand name Symdeko. Cystic fibrosis, which affects about 75,000 people in North America, Europe and Australia, is caused by a defective or missing protein and results in serious lung infections, declining lung function and often early death.
The followed triple combination data released in November involving VX-659 that showed a 14 percent lung function improvement in these patients.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: WSJ - 🏆 98. / 63 Read more »